Actively Recruiting
Cardiac Angiosarcoma International Registry
Led by Immune Oncology Research Institute · Updated on 2026-02-18
500
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are: 1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
CONDITIONS
Official Title
Cardiac Angiosarcoma International Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of cardiac angiosarcoma by histopathological examination, including subtypes like hemangiosarcoma and epithelioid hemangiosarcoma
- Diagnosis made between January 2015 and January 2035
- Participants from various geographical locations
- Patients who have received any treatment (surgery, chemotherapy, immunotherapy, or radiation) for cardiac angiosarcoma
- Informed consent obtained for prospective patients
- Availability of relevant clinical data including demographics, tumor details, treatments, and outcomes
- Willingness to participate in follow-up assessments
You will not qualify if you...
- Patients who do not provide informed consent
- Cases where heart involvement is due to spread from another primary cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yeolyan Hematology and Oncology Center
Yerevan, Armenia, 0014
Actively Recruiting
Research Team
A
Aharon Tsaturyan, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here